HUTCHMED
HUTCHMED Divests 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million to Focus on Core Oncology Pipeline
HUTCHMED, Shanghai Hutchison Pharmaceuticals, divestment, oncology pipeline, antibody-targeted therapy conjugates (ATTCs), strategic focus, profitability.
HUTCHMED Withdraws Fruquintinib Application for Second-Line Gastric Cancer Treatment in China
HUTCHMED, fruquintinib, gastric cancer, second-line treatment, China, NDA withdrawal